Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: April 2013

Chapter 11 - Sexual function in the aging male


1. FeldmanHA, GoldsteinI, HatzichristouDGet al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.
2. BaconCG, MittlemanMA, KawachiIet al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139(3):161–8.
3. HydeZ, FlickerL, HankeyGJet al. Prevalence and predictors of sexual problems in men aged 75–95 years: a population-based study. J Sex Med. 2012;9(2):442–53.
4. EganBM, ZhaoY, AxonRN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. J Am Med Assoc. 2010;303(20):2043–50.
5. ReffelmannT, KlonerRA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447–55.
6. SrilathaB, AdaikanPG, ArulkumaranSet al. Sexual dysfunction related to antihypertensive agents: results from the animal model. Int J Impot Res. 1999;11(2):107–13.
7. ParazziniF, RicciE, ChiaffarinoFet al. Diabetes, cardiovascular diseases and risk of erectile dysfunction: a brief narrative review of the literature. Arch Ital Urol Androl. 2009;81(1):24–31.
8. MeldrumDR, GamboneJC, MorrisMAet al. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol. 2011;108(4):599–606.
9. NapoliC, IgnarroLJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res. 2009;32(8):1103–8.
10. LewisRW, Fugl-MeyerKS, BoschRet al. Epidemiology/risk factors of sexual dysfunction. J Sex Med. 2004;1(1):35–9.
11. ChengJY, NgEM, ChenRYet al. Alcohol consumption and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19(4):343–52.
12. BoddiV, CoronaG, MonamiMet al. Priapus is happier with venus than with bacchus. J Sex Med. 2010;7(8):2831–41.
13. YusufS, HawkenS, OunpuuSet al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart Study): case-control study. Lancet. 2004;364(9438):937–52.
14. BrantWO, BellaAJ, LueTF. Erectile and sexual dysfunction in the aging diabetic male. Aging Health. 2006;2(6):1025–34.
15. MatfinG, JawaA, FonsecaVA. Erectile dysfunction: interrelationship with the metabolic syndrome. Curr Diab Rep. 2005;5(1):64–9.
16. LaumannEO, PaikA, RosenRC. Sexual dysfunction in the United States: prevalence and predictors. J Am Med Assoc. 1999;281(6):537–44.
17. BroderickGA, ArgerP. Duplex doppler ultrasonography: noninvasive assessment of penile anatomy and function. Semin Roentgenol. 1993;28(1):43–56.
18. LueTF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802–13.
19. WeinAJ, KavoussiLR, NovickACet al., editors. Campbell-Walsh Urology. 9th edn. Philadelphia, PA: Saunders/Elsevier; 2007.
20. MulliganT, FrickMF, ZurawQCet al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–9.
21. KilminsterS, MullerS, MenonMet al. Predicting erectile function outcome in men after radical prostatectomy for prostate cancer. BJU Int. 2012;110(3):422–6.
22. MulhallJP, Rojaz-CruzC, MullerA. An analysis of sexual health information on radical prostatectomy websites. BJU Int. 2010;105(1):68–72.
23. ChoiWW, FreireMP, SoukupJRet al. Nerve-sparing technique and urinary control after robot-assisted laparoscopic prostatectomy. World J Urol. 2011;29(1):21–7.
24. MundingMD, WessellsHB, DalkinBL. Pilot study of changes in stretched penile length 3 months after radical retropubic prostatectomy. Urology. 2001;58(4):567–9.
25. McVaryK. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. Br J Urol. 2006;97(Suppl. 2):23–8.
26. BarqawiAB, MyersJB, O’DonnellCet al. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int. 2007;100(4):853–7.
27. McVaryKT, RoehrbornCG, KaminetskyJCet al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7.
28. TraishAM, HassaniJ, GuayATet al. Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872–84.
29. ChungSD, KellerJJ, LinHC. A case-control study on the association between chronic prostatitis/chronic pelvic pain syndrome and erectile dysfunction. Br J Urol. 2012;110(5):726–30.
30. AraujoAB, O’DonnellAB, BrambillaDJet al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920–6.
31. KapoorD, GoodwinE, ChannerKSet al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
32. GrecoEA, SperaG, AversaA. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol. 2006;50(5):940–7.
33. BasariaS, CovielloAD, TravisonTGet al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.
34. KantorJ, BilkerWB, GlasserDBet al. Prevalence of erectile dysfunction and active depression: an analytic cross-sectional study of general medical patients. Am J Epidemiol. 2002;156(11):1035–42.
35. ClaytonAH, PradkoJF, CroftHAet al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–66.
36. LatiniDM, PensonDF, LubeckDPet al. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the exploratory comprehensive evaluation of erectile dysfunction study. J Urol. 2003;169(4):1437–42.
37. BrigantiA, SaloniaA, GallinaAet al. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol. 2005;2(5):239–47.
38. BellaAJ, BrantWO, LueTFet al. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol. 2006;13(5):3233–8.
39. EardleyI, DonatucciC, CorbinJet al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7(1 Pt 2):524–40.
40. MulhallJP, JahodaAE, AhmedAet al. Analysis of the consistency of intraurethral prostaglandin e(1) (MUSE) during at-home use. Urology. 2001;58(2):262–6.
41. DerouetH, CaspariD, RohdeVet al. Treatment of erectile dysfunction with external vacuum devices. Andrologia. 1999;31(Suppl. 1):89–94.
42. de la TailleA, DelmasV, AmarEet al. Reasons of dropout from short- and long-term self-injection therapy for impotence. Eur Urol. 1999;35(4):312–17.
43. HsiaoW, BennettN, GuhringPet al. Satisfaction profiles in men using intracavernosal injection therapy. J Sex Med. 2011;8(2):512–17.
44. WilsonSK, SalemEA, CostertonW. Anti-infection dip suggestions for the coloplast titan inflatable penile prosthesis in the era of the infection retardant coated implant. J Sex Med. 2011;8(9):2647–54.
45. Akin-OlugbadeO, ParkerM, GuhringPet al. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3(4):743–8.
46. MontagueDK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am. 2011;38(2):217–25.